Johnson & Johnson JNJ
NYSE JNJ
$270.24 +2.87 (+1.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)

Johnson & Johnson (JNJ) posted Income from Continuing Operations of 5534000000.0 for Q2 2026, up 5.71% sequentially from 5235000000.0 in Q1 2026, and little changed YoY from 5537000000.0 in Q2 2025.

Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Johnson & Johnson has reported Income from Continuing Operations for 18 years, with the latest figure at 5534000000.0 in Q2 2026.

  • Quarterly Income from Continuing Operations changed 0.05% year-over-year to 5534000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21037000000.0 (down 7.17% YoY) and the FY2025 annual result came in at 26804000000.0, up 90.56% from the prior year.
  • Income from Continuing Operations advanced to 5534000000.0 in Q2 2026 per JNJ's latest filing, from 5235000000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 10999000000.0 in Q1 2025 and troughed at 491000000.0 in Q2 2023.
  • A 5-year average of 4474000000.0 and a median of 4400000000.0 in 2022 frame the typical range for Income from Continuing Operations.
  • The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 110.94% in 2023, then jumped 762.93% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 4310000000.0 in 2022, then slipped by 4.13% to 4132000000.0 in 2023, then dropped by 16.97% to 3431000000.0 in 2024, then soared by 49.11% to 5116000000.0 in 2025, then gained by 8.17% to 5534000000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered 5534000000.0, 5235000000.0, and 5116000000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 5.53 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.62 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 2.51 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.50 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -246.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 207.96 Mn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn 17.71 Bn

Historic Data

Download Data
DateValue
Jun 28, 2026 5.53 Bn
Mar 29, 2026 5.24 Bn
Dec 28, 2025 5.12 Bn
Sep 28, 2025 5.15 Bn
Jun 29, 2025 5.54 Bn
Mar 30, 2025 11.00 Bn
Dec 29, 2024 3.43 Bn
Sep 29, 2024 2.69 Bn
Jun 30, 2024 4.69 Bn
Mar 31, 2024 3.26 Bn
Dec 31, 2023 4.13 Bn
Oct 1, 2023 4.31 Bn
Jul 2, 2023 5.38 Bn
Apr 2, 2023 -491.00 Mn
Jan 1, 2023 2.65 Bn
Oct 2, 2022 4.31 Bn
Jul 3, 2022 4.12 Bn
Apr 3, 2022 4.49 Bn
Oct 3, 2021 3.67 Bn
Jul 4, 2021 6.28 Bn